. Author manuscript; available in PMC: 2021 Oct 31.

Published in final edited form as: Cancer Prev Res (Phila). 2020 Oct 23;14(2):215–222. doi: 10.1158/1940-6207.CAPR-20-0348

Table 2:

JPS demographic data and clinical history

	Disease-causing Variant Negative JPS (n=64)	Disease-causing Variant Positive JPS (n=54)		p-value
		SMAD4 (n=27)	BMPR1A (n=27)
Female (%)	42	56		0.123
		61	52	0.511
Age at Diagnosis: Median (range) (years)	5 (2 – 55)	18 (1 – 72)		<0.001
		19 (2 – 54)	18 (1 – 72)	0.996
Age at Last Follow Up: Median (range) (years)	11 (3 – 57)	33.5 (2 – 73)		<0.001
		37 (13 – 65)	27 (2 – 73)	0.394
Years of Follow Up: Median (range) (years)	4.5 (0–30)	5 (0 – 48)		0.350
		8 (0 – 48)	2 (0 – 44)	*<0.001*
Positive Family History for JPS (%)	6	52		<0.001
Positive Family History for JPS (%)		56	48	*0.016*
Presence of Adenomas (%) ^*	0	45		<0.001
		52	38	0.635
Upper GI Polyps (%) ^*	0	57		<0.001
		60	55	0.839
Lower GI Polyps (%) ^*	100	87		0.003
		88	86	0.548

Demographic data, clinical history, polyp location, and adenoma frequency in individuals with JPS, subdivided by no DCV and SMAD4/BMPR1A DCV

Polyp and adenoma burden as measured by lifetime presence of upper (gastric/duodenal) polyps, lower (colonic/rectal) polyps, and adenomas (upper or lower)